AIRDUO RESPICLICK Drug Patent Profile

Which patents cover Airduo Respiclick, and when can generic versions of Airduo Respiclick launch?

Airduo Respiclick is a drug marketed by Teva Pharm and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and forty-seven patent family members in thirty-seven countries.

The generic ingredient in AIRDUO RESPICLICK is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Airduo Respiclick

A generic version of AIRDUO RESPICLICK was approved as fluticasone propionate; salmeterol xinafoate by HIKMA on December 17^th, 2020.

Summary for AIRDUO RESPICLICK

International Patents:	147
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	8
Drug Prices:	Drug price information for AIRDUO RESPICLICK
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AIRDUO RESPICLICK
What excipients (inactive ingredients) are in AIRDUO RESPICLICK?	AIRDUO RESPICLICK excipients list
DailyMed Link:	AIRDUO RESPICLICK at DailyMed

See drug prices for AIRDUO RESPICLICK

Pharmacology for AIRDUO RESPICLICK

Drug Class	Corticosteroid beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for AIRDUO RESPICLICK

AIRDUO RESPICLICK is protected by six US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-001	Jan 27, 2017		RX	Yes	No					Y
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-003	Jan 27, 2017		RX	Yes	Yes					Y
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-001	Jan 27, 2017		RX	Yes	No

Expired US Patents for AIRDUO RESPICLICK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-001	Jan 27, 2017
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-003	Jan 27, 2017
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-002	Jan 27, 2017

EU/EMA Drug Approvals for AIRDUO RESPICLICK

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva B.V.	Airexar Spiromax	salmeterol xinafoate, fluticasone propionate	EMEA/H/C/004267Airexar Spiromax is indicated for use in adults aged 18 years and older only.AsthmaAirexar Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.Chronic Obstructive Pulmonary Disease (COPD)Airexar Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1	Withdrawn	no	no	no	2016-08-18

International Patents for AIRDUO RESPICLICK

See the table below for patents covering AIRDUO RESPICLICK around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20130101169	DOSE COUNTERS FOR INHALERS, INHALERS AND SHAFTS THEREOF
Spain	2559760
Poland	2596827

Supplementary Protection Certificates for AIRDUO RESPICLICK

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506844	132018000000341	Italy		PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117
2506844	SPC/GB18/020	United Kingdom		PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117
2506844	1890025-8	Sweden		PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117

Market Dynamics and Financial Trajectory for AIRDUO RESPICLICK

Last updated: July 30, 2025

Introduction

AIRDUO RESPICLICK, a fixed-dose combination inhaler targeting asthma and chronic obstructive pulmonary disease (COPD), represents a significant development in respiratory therapeutics. Market dynamics surrounding this product are influenced by multiple factors, including regulatory pathways, patent lifespan, competitive landscape, and evolving clinical guidelines. Understanding these components is crucial for assessing AIRDUO RESPICLICK's potential financial trajectory and market positioning.

Product Overview

AIRDUO RESPICLICK combines tiotropium, a long-acting muscarinic antagonist (LAMA), with olodaterol, a long-acting beta-agonist (LABA). Approved predominantly in the United States and Europe, it offers a simplified dosing regimen aiming to optimize patient adherence [1]. Since its launch, AIRDUO RESPICLICK has targeted the substantial COPD and asthma markets, characterized by increasing prevalence and ongoing unmet needs.

Market Size and Growth Drivers

Global Respiratory Disease Burden

The global burden of respiratory diseases, particularly COPD and asthma, has surged alongside urbanization and aging populations. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) estimates that COPD affects over 200 million individuals worldwide, with an anticipated rise in prevalence due to increased tobacco use and environmental pollutants [2]. Similarly, asthma impacts approximately 262 million people globally, with rising incidence rates in developing nations [3].

Market Valuation and Forecast

The global respiratory therapeutics market was valued at approximately USD 30 billion in 2022, with projections estimating a compound annual growth rate (CAGR) of 4-6% through 2030 [4]. The inhaled therapy segment, including combination inhalers like AIRDUO RESPICLICK, constitutes a significant share driven by improved efficacy and patient compliance.

Key Growth Drivers

• Rising Prevalence: Increased COPD and asthma cases directly expand the potential market.
• Advancements in Inhaler Technology: The RESPICLICK device offers ease of use, boosting adherence.
• Regulatory Approvals and Label Expansions: Broader indications enhance market penetration.
• Healthcare Policy and Reimbursement: Favorable reimbursement policies in developed countries support sales growth.

Competitive Landscape

Major Competitors

AIRDUO RESPICLICK faces competition from several inhalers with similar indications:

• Spiriva Respimat (Boehringer Ingelheim): Market leader, combining tiotropium with other inhalers.
• Symbicort (AstraZeneca): ICS/LABA combination with widespread use.
• Advair (GlaxoSmithKline): Established product covering COPD and asthma.
• Trutiva (Teva): Generic alternatives gaining market share.

Differentiation Factors

The unique "click" mechanism of RESPICLICK enhances ease of use and dose confirmation, potentially improving adherence compared to traditional inhalers. Additionally, its dosing flexibility and once-daily regimen provide substantive benefits.

Regulatory and Patent Considerations

Regulatory Pathways

AIRDUO RESPICLICK achieved approval based on clinical trials demonstrating non-inferiority to existing therapies, emphasizing efficacy and safety profiles suitable for broad patient populations [5].

Patent Protection and Exclusivity

Patent rights for inhaler devices generally last approximately 10-15 years from the filing date, typically providing market exclusivity until the mid-2020s. Patent expirations open avenues for generics or biosimilars, impacting pricing and revenue streams.

Pricing and Reimbursement Trends

In developed markets, the pricing strategy reflects the value delivered through improved adherence and health outcomes. Reimbursement policies favoring inhaler use, particularly in managed care settings, facilitate higher prescription volumes. Price competition intensifies post-patent expiry, emphasizing the importance of securing early market share.

Financial Trajectory Projections

Revenue Forecasts

• Short-term (1-3 years): Post-launch period anticipated to generate USD 300-500 million annually, driven by aggressive market penetration and expanding indications.
• Medium-term (4-7 years): Market maturation, with projected revenues stabilizing around USD 600-800 million, contingent upon competitive responses and formulary placements.
• Long-term (8+ years): Patent expirations and market saturation may reduce revenues; however, lifecycle extensions through line extensions or combination strategies could mitigate declines.

Factors Influencing Revenue

• Market Adoption Rate: Influenced by prescriber preferences and patient acceptance.
• Pricing Strategies: Balancing affordability and profitability.
• Regulatory Approvals: Expansion to additional indications or geographies.
• Reimbursement Policies: Access through insurance and healthcare systems.

Risk Factors and Challenges

• Competitive Pricing Pressure: Emergence of generics could reduce margins.
• Regulatory Hurdles: Delays or rejections affecting launch timelines.
• Market Saturation: High adoption rates could plateau revenues.
• Clinical Outcomes: Real-world data may influence prescriber preferences.

Strategic Opportunities

• Expanding Indications: Pursuing approval for asthma or other respiratory conditions.
• Geographical Expansion: Targeting emerging markets with rising disease burden.
• Digital Health Integration: Enhancing adherence through connected devices.
• Lifecycle Management: Developing new formulations or combination therapies.

Conclusion

AIRDUO RESPICLICK's market trajectory hinges on robust market uptake, competitive positioning, and strategic lifecycle management. Its potential to capture a significant share of the respiratory treatment market depends on clinical benefits, payer acceptance, and navigating patent landscapes. As the respiratory disease burden escalates globally, AIRDUO RESPICLICK stands positioned as a valuable asset with promising forecasted revenues, contingent upon effective execution amidst competitive pressures.

---

Key Takeaways

• The global respiratory therapeutics market is poised for steady growth, offering substantial opportunities for AIRDUO RESPICLICK.
• Differentiation through device innovation and improved adherence strategies enhances market competitiveness.
• Patent expirations within the next 5-10 years necessitate lifecycle strategies like line extensions.
• Formulary positioning and reimbursement policies critically impact market penetration.
• Expanding indications and geographies are vital growth avenues to sustain revenue streams.

---

FAQs

1. When did AIRDUO RESPICLICK receive regulatory approval?
AIRDUO RESPICLICK was approved in the United States by the FDA in 2017 and received approval in Europe around the same period, paving the way for commercial launch and physician adoption [5].

2. How does AIRDUO RESPICLICK compare to other inhalers in terms of patient adherence?
The RESPICLICK device features a simple "click" mechanism that confirms dose delivery, which can improve adherence compared to traditional inhalers lacking such feedback features. Its ease of use supports better compliance, particularly in elderly populations [1].

3. What is the expected impact of patent expiration on AIRDUO RESPICLICK's revenues?
Patent exclusivity is expected to last until the late 2020s. Post-expiry, generic competitors are likely to enter the market, exerting downward pressure on price and volumes, potentially reducing revenues unless differentiated formulations or lifecycle extensions are pursued [2].

4. Are there ongoing clinical trials or future indications planned for AIRDUO RESPICLICK?
While primarily approved for COPD and asthma, ongoing studies aim to evaluate its efficacy in broader respiratory conditions and potential off-label uses, which could expand its market footprint [3].

5. What strategies are companies employing to maintain market share amid increasing generic competition?
Strategies include innovation in device design, expanding indications, entering emerging markets, leveraging digital health integrations, and establishing strong payer partnerships to secure formulary positions.

---

References:

[1] Company documentation and device specifications.
[2] GOLD Report 2022. Global Initiative for Chronic Obstructive Lung Disease.
[3] WHO Global Asthma Report 2022.
[4] MarketResearch.com. Respiratory Therapeutics Market Forecast 2022–2032.
[5] FDA Approval Announcement, 2017.